Dr. Adnan M. Mjalli
Dr. Adnan M. M. Mjalli is an internationally recognized serial entrepreneur in the business of drug discovery and development of new medicines in the pharmaceutical and biotechnology space, in addition to novel therapies derived from Human and Earth Biome technologies Including bioremediation. Dr. Mjalli is the executive chairman of MIG USA, a private holding company located in High Point, NC. Some of MIG USA’s operating companies are: High Point Clinical Trials Center, Bien-Etre Labs, Gaia Klēn, Oasis, Vitak, Sam’s Investment Group, Falcon Crest Investments, and Noor Brands Company.
Dr. Mjalli founded TransTech Pharma (now VTV therapeutics) and Pharmacore (now Cambrex) and served as Chairman and CEO of both companies from December 1999 – November 2017.
Dr. Mjalli’s work goes well beyond the drug discovery and development arena. He is the founder of more than 20 other companies in many areas including education, energy, agriculture, construction, development, real estate, and trade. These companies focus on Dr. Mjalli’s core values: science, education, technology and the advancement of human capital in developing countries.Dr. Mjalli obtained his Ph.D. in Medicinal Chemistry in 1989 from the University of Exeter, UK. His post-doctoral work was completed at the University of Rochester under Professor Richard S. Schlessinger. Since that time, Dr. Mjalli has held various positions of increasing responsibility in research and senior management at several pharmaceutical and biotechnology companies including Merck & Co., Inc. and Ontogen Corporation. To date, Dr. Mjalli has authored hundreds of scientific papers, book chapters and has been named as an inventor on more than 700 patents and patent applications.Dr. Mjalli also served on the Board of Directors of Siga Technologies, the North Carolina Biotechnology Center, the Guilford Technology Community College (GTCC) Board, and the High Point Economic Development Corporation. Currently, Dr. Mjalli serves on the High Point University Board, The Foundation Board of GTCC, High Point Chamber of Commerce, and is a member of the American Chemical Society,
Dr. Mjalli has raised, structured, negotiated, and concluded several multibillion-dollar deals with major global pharmaceutical and biotechnology companies.